These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Round table: Post-marketing evaluation of fertility-regulating drugs as viewed by the pharmaceutical industry. Hum Reprod; 1987 Apr; 2(3):241-63. PubMed ID: 3597744 [No Abstract] [Full Text] [Related]
23. [Notification of possible adverse reactions to drugs in medical publications]. Laporte JR; Capellà D Med Clin (Barc); 1984 Oct; 83(11):474. PubMed ID: 6503426 [No Abstract] [Full Text] [Related]
24. Postmarketing surveillance. Oleen MA Can J Hosp Pharm; 1987 Oct; 40(5):171-2, 179-80. PubMed ID: 10284449 [TBL] [Abstract][Full Text] [Related]
26. Biological indicator test packs: a survey of user practices. Smith DE J Healthc Mater Manage; 1988; 6(4):38, 40-2. PubMed ID: 10287653 [No Abstract] [Full Text] [Related]
28. The desire to regulate: the wish to discover. Lasagna L Drugs Exp Clin Res; 1987; 13(11):659-64. PubMed ID: 3443041 [TBL] [Abstract][Full Text] [Related]
29. Postmarketing surveillance of adverse drug reactions. Castle WM; Lewis JA Br Med J (Clin Res Ed); 1984 May; 288(6428):1458-9. PubMed ID: 6426604 [No Abstract] [Full Text] [Related]
30. Postmarketing surveillance methodologies. Edlavitch SA Drug Intell Clin Pharm; 1988 Jan; 22(1):68-78. PubMed ID: 3280280 [TBL] [Abstract][Full Text] [Related]
31. Postmarketing surveillance of adverse reactions to drugs. Rawlins MD Br Med J (Clin Res Ed); 1984 Mar; 288(6421):879-80. PubMed ID: 6423125 [No Abstract] [Full Text] [Related]
32. Techniques of postmarketing surveillance. An overview. Carson JL; Strom BL Med Toxicol; 1986; 1(4):237-46. PubMed ID: 3537618 [No Abstract] [Full Text] [Related]
34. Postmarketing surveillance of adverse reactions to drugs. Inman WHW Br Med J (Clin Res Ed); 1984 Apr; 288(6424):1155-6. PubMed ID: 6424767 [No Abstract] [Full Text] [Related]
35. Discovery of adverse drug reactions. A comparison of selected phase IV studies with spontaneous reporting methods. Rossi AC; Knapp DE; Anello C; O'Neill RT; Graham CF; Mendelis PS; Stanley GR JAMA; 1983 Apr 22-29; 249(16):2226-28. PubMed ID: 6834622 [No Abstract] [Full Text] [Related]
36. [Contribution of data of efficacy trials to judge the improvement of the medical usefulness of a drug]. Bouvenot G; Eschwège E Therapie; 1992; 47(1):17-9. PubMed ID: 1523589 [TBL] [Abstract][Full Text] [Related]
37. Post-marketing surveillance of new drugs. Buckley EG J R Coll Gen Pract; 1987 Aug; 37(301):337-8. PubMed ID: 3448222 [No Abstract] [Full Text] [Related]
38. The computerized on-line Medicaid pharmaceutical analysis and surveillance system: a new resource for postmarketing drug surveillance. Strom BL; Carson JL; Morse ML; LeRoy AA Clin Pharmacol Ther; 1985 Oct; 38(4):359-64. PubMed ID: 3899458 [No Abstract] [Full Text] [Related]
39. [Presentation of data in drug surveillance and bases for a decision]. Lagier G Rev Med Interne; 1986 Nov; Spec No():41-4. PubMed ID: 3809779 [TBL] [Abstract][Full Text] [Related]